Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 2021-02-17 20:00
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib 2021-01-29 20:26
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals 2021-01-28 22:03
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease 2021-01-06 20:24
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib 2020-12-31 22:38
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue 2020-12-22 20:38
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model 2020-12-16 00:42
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 2020-11-30 10:45
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences 2020-11-25 07:00
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease 2020-11-20 21:00
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease 2020-11-20 07:00
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib 2020-11-19 20:21
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks 2020-11-19 07:00
1 2